Bring clarity to the early medical strategy and the tactics in the responsible projects by their own medical/scientific knowledge/interpretation/judgement and deep understanding of external voice/environment as medical/scientific/clinical research expert.
Develop patient centered early Medical strategy and initial IEP aligned with TA strategy (local and global), including the analysis of patient needs and Healthcare system (HCS) environment.
Act as “Medical representatives” in JPT and the agile project
Drive the actionable insight cycle by giving regular clear direction to JPT/Pre-JBT, and utilizing the insights to update the early product strategy.
Lead/Execute the early evidence generation strategy in the responsible projects as a medical/scientific/clinical research expert, though the Scientific publications and innovative medical solutions closely collaborating with internal and external stakeholders.
Plan and execute initial IEP including evidence generation plan by leading cross functional team
Plan, develop, execution and dissemination of RWE and pre-clinical research (if necessary)
Co-generates HCS relevant data generation including implementation science in collaboration with Value & Access (V&A), Comms & Patient Engagement (PE) and GDD.
Lead to optimize a process of initial IEP development (including project prioritization of IEP development) and its update in collaboration with MEE, V&A and GDD.
Contribute to development process and portfolio prioritization to ensure sustainable Innovative Medicine International-Japan (IMI-J) growth by maximizing the value of pipeline in close collaboration with NPP-LEX and GDD as a representative from Medical
Bring clarity to key decision making points in development process (e.g. DDP, FDP etc.) based on medical insights
Input to local TPP optimization
Contribute to portfolio prioritization and Japan Portfolio Review (JPFR)
Lead/Execute PE strategy and HCS strategy as key role, together with V&A and Comms&PE
